SHIONOGI & CO LTD

Shionogi’s new oral broad‑spectrum antiviral moves into Phase II, backed by cGMP manufacturing, FDA orphan status, and a host‑targeted design that cuts resistance risks and could reshape global pandemic preparedness.

Hikma names Rebecca Hall CFO, linking Shionogi‑linked ViiV expertise to stronger financial leadership and smoother antiretroviral supply chains.

Shionogi expands globally, acquiring rare‑disease and infectious‑disease firms and boosting U.S. manufacturing to strengthen supply chains and diversify its drug portfolio.

Explore how Shionogi & Co. Ltd’s long‑acting HIV therapies gain market share, leverage real‑world data, and navigate patent cliffs for future growth.

Shionogi’s 22% stake in ViiV Healthcare boosts HIV treatment access—leveraging AI adherence, stigma‑free pricing, and emerging‑market expansion for higher impact and profit.

Shionogi’s FY 2026 results show 7.8 % revenue growth and a 17.3 % operating margin, driven by new oncology and immunotherapy launches and cost‑saving digital investments.

Shionogi’s May 12 earnings forecast shows EPS and revenue growth fueled by the RADICAVA acquisition, expanding ALS therapy options and strengthening its rare‑disease portfolio.

Shionogi’s 21% stake in ViiV Healthcare boosts its HIV portfolio, unlocking long‑acting therapies and cost‑efficient manufacturing for a high‑barrier market.

Shionogi’s 2025 results show a strong operating margin driven by a broad‑spectrum antibacterial partnership, with strategic IP, market‑access plans, and M&A options poised to sustain growth amid patent cliffs and fierce competition.

Shionogi partners with Cumulus Neuroscience to boost cognitive drug trials while expanding its antifungal portfolio, positioning itself for growth in high‑potential markets.